PancNext®

PancNext is a next generation sequencing panel that simultaneously analyzes 13 genes associated with increased risk for pancreatic cancer.
Genetic Testing for Hereditary Cancer Patient Consent English | Spanish
Quick Reference
Test Code: 8042 Test Name: PancNext® TAT: 14-21 days Genes: 13
Test Code: 8064 Test Name: PancNext® plus Pancreatitis TAT: 14-21 days Genes: 19

+RNAinsight®

Add +RNAinsight to your genetic test order today.

Learn more

Ordering Options

We offer family variant testing at no additional cost

for all blood relatives of patients who undergo full single gene sequencing, multigene panel testing or exome sequencing at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant. No-cost testing of blood relatives must be completed within 90 days of the original report date. Whenever possible, more closely related relatives should be tested before more distant relatives.

Order Now

Why Is This Important?

  1. Option to modify frequency and initial age of cancer screening, as appropriate
  2. Consideration of risk-reducing measures, as appropriate 
  3. Option to tailor chemotherapy strategies and/or determine eligibility for clinical trials 
  4. Identify at-risk family members 

When To Consider Testing

  • Personal history of pancreatic cancer at any age
  • First-degree relative (parent, sibling, or child) with pancreatic cancer at any age
  • Multiple primary cancers in the same person (e.g. pancreatic and breast cancer)
  • Multiple close family members with pancreatic, breast, colorectal, uterine, ovarian, and/or melanoma*

* On the same side of the family

Mutation Detection Rate

PancNext can detect >99.9% of described mutations in the included genes listed above, when present (analytic sensitivity).

Test Description

PancNext analyzes 13 genes (listed above). These  genes (excluding EPCAM) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. The inversion of coding exons 1-7 of the MSH2 gene and the BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) are detected by NGS and confirmed by MLPA. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection.  Potentially homozygous variants, variants in regions complicated by pseudogene interference, and variant calls not satisfying depth of coverage and variant allele frequency quality thresholds are verified by Sanger sequencing.   Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all sequenced genes using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray. For EPCAM, only gross deletions encompassing the 3’ end of the gene are reported. For APC, all promoter 1B gross deletions as well as single nucleotide substitutions within the promoter 1B YY1 binding motif (NM_001127511 c.-196_c.-186) are analyzed and reported. For PMS2, gross deletion/duplication analysis is performed using MLPA. If a deletion is detected in exons 13, 14, or 15 of PMS2, double stranded sequencing of the appropriate exon(s) of the pseudogene, PMS2CL, will be performed to determine if the deletion is located in the PMS2 gene or pseudogene. 

View Full Menu

Search Results

Start your search...